Patent ID: 8355877

Claim:
A system for assessing a patient's likelihood of responding favorable to a weight-loss pharmaceutical agent, comprising: an NMR spectrometer configured to measure triglyceride rich lipoprotein (TRL) V6; and at least one processor in communication with the NMR spectrometer, wherein the at least one processor is configured to predict whether a patient is likely to respond favorably to the weight loss pharmaceutical agent based on at least one NMR derived TRL V6 measurement on at least one patient biosample taken after the patient has been administered a fat load in conjunction with administration of the weight loss pharmaceutical agent, wherein the at least one processor is configured to compare said TRL V6 measurement with either a standard TRL V6 measurement in response to the fat load in the absence of the weight loss pharmaceutical agent, or with a second NMR derived TRL V6 measurement on at least one patient biosample taken after the patient has been administered a fat load in the absence of the weight loss pharmaceutical agent, and determine whether there is a significant reduction in TRL V6 for the sample taken in conjunction with the weight loss pharmaceutical agent, wherein a significant reduction in TRL V6 indicates a patient is likely to respond favorably to the weight loss pharmaceutical agent.